pramipexole has been researched along with alpha-synuclein in 11 studies
| Studies (pramipexole) | Trials (pramipexole) | Recent Studies (post-2010) (pramipexole) | Studies (alpha-synuclein) | Trials (alpha-synuclein) | Recent Studies (post-2010) (alpha-synuclein) |
|---|---|---|---|---|---|
| 1,103 | 219 | 517 | 10,821 | 29 | 8,011 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (18.18) | 29.6817 |
| 2010's | 7 (63.64) | 24.3611 |
| 2020's | 2 (18.18) | 2.80 |
| Authors | Studies |
|---|---|
| Kakimura, J; Kitamura, Y; Kohno, Y; Nomura, Y; Takata, K; Taniguchi, T | 1 |
| Ariga, H; Inden, M; Kitamura, Y; Shibaike, T; Taira, T; Takata, K; Tamaki, A; Taniguchi, T; Yamamoto, A; Yanagida, T; Yasui, H | 1 |
| Chau, KY; Cooper, JM; Schapira, AH | 1 |
| Afonso-Oramas, D; Barroso-Chinea, P; Castro-Hernández, J; Cruz-Muros, I; González-Hernández, T; Millan, MJ; Moratalla, R; Salas-Hernández, J | 1 |
| da Costa, AN; Dardou, D; Dremier, S; Durif, F; Hafidi, A; Hanon, E; Loiodice, S; Ouachikh, O; Winlow, P | 1 |
| Dutta, AK; Joshi, GS; Luo, D; Todi, SV; Yedlapudi, D | 1 |
| Dardou, D; Durif, F; Fleurance, R; Gryshkova, V; Hafidi, A; Loiodice, S; McGhan, P; Nogueira da Costa, A | 1 |
| Chen, NH; Heng, Y; Huang, JY; Mou, Z; Yuan, YH; Zhang, QS | 1 |
| Liu, X; Qi, L; Sang, Q; Sun, W; Sun, Y; Wang, L; Wang, W; Zhang, H | 1 |
| Gao, H; Jiang, S; Mao, JP; Wang, D; Wang, YL; Yang, XL | 1 |
| Belloso-Iguerategui, A; Cotman, CW; Fernández-Irigoyen, J; Gago, B; Merino-Galan, L; Prieto, GA; Quiroga-Varela, A; Rodríguez-Chinchilla, T; Rodríguez-Oroz, MC; Santamaria, E; Zamarbide, M | 1 |
11 other study(ies) available for pramipexole and alpha-synuclein
| Article | Year |
|---|---|
Release and aggregation of cytochrome c and alpha-synuclein are inhibited by the antiparkinsonian drugs, talipexole and pramipexole.
Topics: 1-Methyl-4-phenylpyridinium; alpha-Synuclein; Antiparkinson Agents; Azepines; Benzothiazoles; Caspases; Cell-Free System; Cytochrome c Group; Cytosol; Deoxyadenine Nucleotides; Dose-Response Relationship, Drug; Enzyme Activation; Humans; Nerve Tissue Proteins; Organelles; Pramipexole; Synucleins; Thiazoles; Tumor Cells, Cultured | 2001 |
Neuroprotective effect of the antiparkinsonian drug pramipexole against nigrostriatal dopaminergic degeneration in rotenone-treated mice.
Topics: alpha-Synuclein; Animals; Antiparkinson Agents; Apoptosis; Benzothiazoles; Cell Line, Tumor; Corpus Striatum; Cytochromes c; Dopamine; Dose-Response Relationship, Drug; Humans; Hydrogen Peroxide; Hydroxyl Radical; Male; Mice; Mice, Inbred C57BL; Nerve Degeneration; Neural Pathways; Neurotoxins; Oxidative Stress; Parkinsonian Disorders; Pramipexole; Proto-Oncogene Proteins c-bcl-2; Rotenone; Substantia Nigra; Uncoupling Agents | 2009 |
Pramipexole reduces phosphorylation of α-synuclein at serine-129.
Topics: alpha-Synuclein; Antiparkinson Agents; Benzothiazoles; Casein Kinase II; Cell Line, Tumor; Humans; Phosphorylation; Pramipexole; Serine | 2013 |
Prolonged treatment with pramipexole promotes physical interaction of striatal dopamine D3 autoreceptors with dopamine transporters to reduce dopamine uptake.
Topics: alpha-Synuclein; Animals; Antidepressive Agents; Antiparkinson Agents; Autoreceptors; Benzothiazoles; Corpus Striatum; Dimerization; Dopamine; Dopamine Agonists; Dopamine Plasma Membrane Transport Proteins; Male; Mice, Inbred C57BL; Mice, Knockout; Pramipexole; Receptors, Dopamine D3 | 2015 |
Pramipexole induced place preference after L-dopa therapy and nigral dopaminergic loss: linking behavior to transcriptional modifications.
Topics: alpha-Synuclein; Animals; Antiparkinson Agents; Benzothiazoles; Corpus Striatum; Dopamine; Female; Humans; Impulsive Behavior; Levodopa; Male; Parkinson Disease, Secondary; Pramipexole; Rats; Receptor, Metabotropic Glutamate 5 | 2017 |
Inhibition of alpha-synuclein aggregation by multifunctional dopamine agonists assessed by a novel in vitro assay and an in vivo Drosophila synucleinopathy model.
Topics: alpha-Synuclein; Animals; Benzothiazoles; Biological Assay; Circular Dichroism; Disease Models, Animal; Dopamine Agonists; Drosophila melanogaster; Eye; PC12 Cells; Pramipexole; Protein Aggregates; Protein Structure, Secondary; Rats; Rifampin; Tetrahydronaphthalenes | 2016 |
Striatal changes underlie MPEP-mediated suppression of the acquisition and expression of pramipexole-induced place preference in an alpha-synuclein rat model of Parkinson's disease.
Topics: alpha-Synuclein; Animals; Benzothiazoles; Corpus Striatum; Dopamine; Excitatory Amino Acid Antagonists; Impulsive Behavior; Male; Nucleus Accumbens; Parkinson Disease; Pramipexole; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Metabotropic Glutamate 5; Receptors, Glutamate; Up-Regulation | 2017 |
Reassessment of subacute MPTP-treated mice as animal model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Antiparkinson Agents; Astrocytes; Behavior, Animal; Benserazide; Benzothiazoles; Blood-Brain Barrier; Chromatography, High Pressure Liquid; Corpus Striatum; Disease Models, Animal; Drug Combinations; Levodopa; Male; Mice; Mice, Inbred C57BL; Microscopy, Electron; Parkinsonian Disorders; Pramipexole; Selegiline | 2017 |
CircSNCA downregulation by pramipexole treatment mediates cell apoptosis and autophagy in Parkinson's disease by targeting miR-7.
Topics: alpha-Synuclein; Antiparkinson Agents; Apoptosis; Autophagy; Down-Regulation; Gene Expression Regulation; Humans; MicroRNAs; Parkinson Disease; Pramipexole; RNA, Messenger | 2018 |
Pramipexole attenuates 6-OHDA-induced Parkinson's disease by mediating the Nurr1/NF-κB pathway.
Topics: alpha-Synuclein; Animals; Antiparkinson Agents; Disease Models, Animal; NF-kappa B; Nuclear Receptor Subfamily 4, Group A, Member 2; Oxidopamine; Parkinson Disease; Pramipexole; Rats; Signal Transduction | 2021 |
Hippocampal synaptic failure is an early event in experimental parkinsonism with subtle cognitive deficit.
Topics: alpha-Synuclein; Animals; Cognition; Dopamine; Dopaminergic Neurons; Hippocampus; Humans; Levodopa; Neurotransmitter Agents; Parkinson Disease; Parkinsonian Disorders; Pramipexole; Rats | 2023 |